|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.29 USD | +5.99% |
|
+12.94% | +6.22% |
| 06-16 | Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027 | MT |
| 06-16 | Avalo Therapeutics Expands Pipeline with AVTX-010, A Long-Acting Next-Generation Anti-Il-1? Antibody | CI |
| Market Cap | 1.01B 888M 820M 765M 1.44B 95.87B 1.47B 9.86B 3.81B 47.29B 3.81B 3.72B 164B | P/E 2026 * |
-7.66x | P/E 2027 * | -6.36x |
|---|---|---|---|---|---|
| Enterprise Value | 597M 523M 483M 451M 849M 56.47B 868M 5.81B 2.24B 27.86B 2.24B 2.19B 96.72B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
98.27% | Yield 2026 * |
0.06% | Yield 2027 * | - |
| 1 day | +5.99% | ||
| 1 week | +12.94% | ||
| Current month | +20.94% | ||
| 1 month | +20.94% | ||
| 3 months | +38.88% | ||
| 6 months | +3.93% | ||
| Current year | +6.22% |
| 1 week | 17.63 |  | 19.48 |
| 1 month | 12.52 | | 19.48 |
| Current year | 12.51 | | 24.27 |
| 1 year | 4.61 | | 24.27 |
| 3 years | 3.39 | | 95.52 |
| 5 years | 3.39 | | 9,878.32 |
| 10 years | 3.39 | | 22,031.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 72 | 13/02/2022 |
| Director of Finance/CFO | 42 | 13/02/2022 | |
Kathleen Cohen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Garry Neil
CHM | Chairman | 72 | 07/08/2022 |
Gilla Kaplan
BRD | Director/Board Member | 78 | 11/10/2020 |
Samantha Truex
BRD | Director/Board Member | 55 | 27/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-22 | Fiscal year | Chief Technology Officer | 4,350 | 0.0083% | ||
| 06-22 | Free | Director | 40,200 | 0.0765% | ||
| 06-09 | Tax | Chief Financial Officer | -138 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.99% | +12.94% | +303.56% | -78.28% | 1.01B | |
| +3.57% | +0.05% | +73.14% | +128.87% | 55.78B | |
| +6.76% | +18.10% | +91.66% | +104.09% | 55.66B | |
| +3.33% | +4.51% | -11.68% | -11.91% | 23.84B | |
| +1.32% | +6.22% | +5.28% | +415.45% | 22.7B | |
| +7.64% | +8.28% | +40.68% | -28.29% | 16.12B | |
| -0.89% | +5.71% | +24.30% | +186.29% | 13.64B | |
| +9.96% | +15.98% | +157.65% | +310.89% | 14.8B | |
| +2.85% | +2.81% | +75.32% | +139.44% | 12.16B | |
| +6.17% | +10.22% | +163.15% | +166.44% | 11.85B | |
| Average | +4.38% | +7.96% | +92.31% | +133.30% | 22.76B | |
| Weighted average by Cap. | +4.34% | +7.73% | +68.11% | +142.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -85.49M -74.86M -69.11M -64.53M -121M -8.08B -124M -832M -321M -3.99B -321M -314M -13.84B | -109M -95.15M -87.84M -82.03M -154M -10.27B -158M -1.06B -408M -5.07B -408M -399M -17.6B |
| Net Debt | -417M -365M -337M -315M -592M -39.4B -606M -4.05B -1.56B -19.44B -1.56B -1.53B -67.48B | -303M -265M -245M -229M -431M -28.67B -441M -2.95B -1.14B -14.14B -1.14B -1.11B -49.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/06/26 | US$19.29 | +5.99% | 1,580,604 |
| 26/06/26 | US$18.20 | +1.11% | 8,576,599 |
| 25/06/26 | US$18.00 | -0.88% | 1,689,269 |
| 24/06/26 | US$18.16 | +1.85% | 1,286,953 |
| 23/06/26 | US$17.83 | +4.39% | 1,969,535 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AVTX Stock
Select your edition
All financial news and data tailored to specific country editions
